CompletedPhase 2

Measure of Pharmacokinetic Parameters and Adherence With MEMS in Naive HIV Infected Patients Treated With Reyataz Once Daily Combined With Norvir and Truvada

France35 participantsStarted 2008-01

Plain-language summary

the trial assessed the pharmacokinetics and long term plasma exposure of the following antiretrovirals: atazanavir when combined to ritonavir and the tenofovir/emtricitabine fixed-dose combination. All drugs will be delivered in MEMS electronic device to monitor dosing history.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Naïve of treatment HIV -1 infected patients * CD4 above 100/mm3 Exclusion Criteria: * pregnancy * renal failure * hepatitic disease * ongoing opportunistic disease * Hb under 8g/dl; platelets under 50 000/mm3; neutrophils under 750/mm3; Prothrombin index under 80%, Ca or Ph \> 2.5 N * drugs interacting with investigational drugs

What they're measuring

pharmacokinetic parameters of atazanavir (ATV) when combined with ritonavir (RTV) and tenofovir/emtricitabine

Timeframe: week 4

Trial details

NCT IDNCT00528060

SponsorFrench National Agency for Research on AIDS and Viral Hepatitis

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2008-11

View on ClinicalTrials.gov More HIV Infections trials